Centessa Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Centessa Pharmaceuticals's estimated annual revenue is currently $7.5M per year.
- Centessa Pharmaceuticals's estimated revenue per employee is $90,361
- Centessa Pharmaceuticals's current valuation is $801M. (January 2022)
Employee Data
- Centessa Pharmaceuticals has 83 Employees.
- Centessa Pharmaceuticals grew their employee count by 9% last year.
Centessa Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Clinical Consultant and Consulting Chief Medical Officer | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | SVP, Biologics CMC | Reveal Email/Phone |
6 | VP, CMC & Analytical R&D | Reveal Email/Phone |
7 | VP, Global Team Leader | Reveal Email/Phone |
8 | VP, Clinical Development Operations | Reveal Email/Phone |
9 | VP, Global Clinical Operations | Reveal Email/Phone |
10 | General Counsel | Reveal Email/Phone |
What Is Centessa Pharmaceuticals?
N/A
Total Funding
83
Number of Employees
$7.5M
Revenue (est)
9%
Employee Growth %
$801M
Valuation
N/A
Accelerator
Centessa Pharmaceuticals News
2022-04-20 - Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded by ...
Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded by Zacks Investment Research to Hold. Posted by admin on Apr 26th, 2022.
2022-04-13 - Zacks Investment Research Lowers Centessa ...
According to Zacks, Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover,...
2022-03-22 - Centessa Pharmaceuticals Reports Fourth Quarter and 2021 ...
Centessa Pharmaceuticals plc (Centessa) is a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine...
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.3M | 83 | 4% | N/A |
#2 | $12.5M | 83 | 2% | N/A |
#3 | $7.5M | 83 | 17% | N/A |
#4 | $7.5M | 83 | 6% | N/A |
#5 | $27.2M | 83 | 20% | N/A |
